CanSino Biologics

CanSino Biologics (also known as CanSinoBIO) is a biopharmaceutical company based in Tianjin, China. The company specializes in the research, development, manufacturing, and commercialization of vaccines for human use.

History

CanSino Biologics was founded in 2009 by a team of experienced scientists with expertise in the development of vaccines. The company's name, CanSino, is derived from the names of Canada and China, reflecting the international background of its founding team.

Products and Research

CanSino Biologics has a diverse product portfolio, including vaccines for tuberculosis, meningitis, and pneumonia. The company is also involved in the development of vaccines for emerging infectious diseases, such as the Ebola virus and the COVID-19 virus.

In 2020, CanSino Biologics gained international attention for its work on a COVID-19 vaccine, known as Convidecia. This vaccine was one of the first to enter clinical trials and has been approved for use in several countries.

Financial Information

CanSino Biologics is a publicly traded company, listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange. The company has experienced significant growth in recent years, driven by the global demand for vaccines.

See Also

• Biopharmaceutical
• Vaccine
• COVID-19 vaccine
• Convidecia

References

<img src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Searchtool.svg/40px-Searchtool.svg.png" alt="Stub icon" width="40" height="40" />

This biopharmaceutical related article is a stub. You can help WikiMD by expanding it.